SAB BIOTHERAPEUTICS, INC. Proceeds from Sale and Maturity of Marketable Securities
SAB BIOTHERAPEUTICS, INC. (SABS) reported Proceeds from Sale and Maturity of Marketable Securities of $84.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $9.71M, a 85.04% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $74.60M, a 1473.26% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $11.27M, a 5.38% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $364.00, a 99.99% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $21.26M, a 17.66% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $25.82M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 6 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $9.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $84.31M 10-Q · filed 2026-08-06 | $95.58M derived: sum of 3 quarters · filed 2026-08-06 | $95.58M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $74.60M 10-Q · filed 2026-05-12 | $85.87M derived: sum of 2 quarters · filed 2026-05-12 | $85.87M derived: sum of 3 quarters · filed 2026-05-12 | $91.12M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $11.27M derived: sum of 2 quarters · filed 2026-03-09 | $16.52M derived: sum of 3 quarters · filed 2026-08-06 | $21.26M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $364.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.25M derived: sum of 2 quarters · filed 2026-08-06 | $9.99M 10-Q · filed 2025-11-14 | $20.69M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $5.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.99M 10-Q · filed 2026-08-06 | $9.99M 10-Q · filed 2025-08-07 | $20.69M derived: sum of 3 quarters · filed 2026-08-06 | $24.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.74M 10-Q · filed 2026-05-12 | $15.44M derived: sum of 2 quarters · filed 2026-05-12 | $19.19M derived: sum of 3 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $14.44M derived: sum of 2 quarters · filed 2026-03-09 | $25.82M 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $15.13M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $11.38M 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |